ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 406,23
-0,52%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Curis Inc (CRIS)

  7. Curis Inc (CRIS) Actualités

CRIS Curis Inc

14,47
-0,05 (-0,34%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Curis Inc CRIS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,05 -0,34% 14,47 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
14,44 14,25 14,6899 14,47 14,52
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
05/4/202413:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/4/202413:30PRNUSCuris to Present at Upcoming Healthcare Conferences in April
12/2/202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202422:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/2/202422:27EDGAR2Form S-3 - Registration statement under Securities Act of..
08/2/202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/2/202414:01EDGAR2Form 8-K - Current report
08/2/202414:00PRNUSCuris Provides Fourth Quarter 2023 Business Update
01/2/202414:00PRNUSCuris to Release Fourth Quarter 2023 Financial Results and..
11/1/202414:13EDGAR2Form 8-K - Current report
05/1/202414:00PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
21/12/202322:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12/12/202314:00PRNUSCuris Announces Initial Combination Study Data from its..
11/12/202314:00PRNUSCuris Presented Clinical Data from the TakeAim Leukemia..
06/12/202314:00PRNUSCuris Announces Three Presentations at ASH
05/12/202314:00PRNUSCuris Enters into Agreement for Emavusertib / Pembrolizumab..
02/11/202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202313:01EDGAR2Form 8-K - Current report
02/11/202313:00PRNUSCuris Provides Third Quarter 2023 Business Update
26/10/202314:30PRNUSCuris to Release Third Quarter 2023 Financial Results and..
06/10/202314:56PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
28/9/202322:05EDGAR2Form 8-K/A - Current report: [Amend]
28/9/202314:54EDGAR2Form 8-K - Current report
12/9/202314:00PRNUSCuris Announces Date for the 2nd Symposium on IRAK4 in..
06/9/202314:13PRNUSCuris to Present at Upcoming Healthcare Conferences in..
18/8/202322:02EDGAR2Form DEF 14A - Other definitive proxy statements
04/8/202322:09EDGAR2Form PRE 14A - Other preliminary proxy statements
03/8/202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:02EDGAR2Form 8-K - Current report
03/8/202322:01PRNUSCuris Provides Second Quarter 2023 Business Update
28/7/202300:25PRNUSCuris to Release Second Quarter 2023 Financial Results and..
06/7/202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/7/202315:28EDGAR2Form 8-K - Current report
06/7/202314:04EDGAR2Form 8-K - Current report
06/7/202314:01PRNUSFDA Removes Partial Clinical Hold on TakeAim Leukemia Study..
06/7/202314:00PRNUSCuris Announces $15.1 Million Registered Direct Offering
05/5/202313:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/5/202322:01PRNUSCuris Provides First Quarter 2023 Business Update

Dernières Valeurs Consultées

NASDAQ
CRIS
Curis
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés